Skip to main content
Figure 1 | BMC Nephrology

Figure 1

From: Higher anti-depressant dose and major adverse outcomes in moderate chronic kidney disease: a retrospective population-based study

Figure 1

Association between anti-depressant dose and adverse events in patients with and without Chronic Kidney Disease (CKD; where CKD was defined by diagnosis codes). There was no difference in association between anti-depressant dose and adverse events in patients with and without CKD (interaction p-value 0.163 and 0.962, respectively for each outcome). Estimates of risks for patients without CKD (n = 112,430) were more precise than for patients with CKD (n = 5,381). Adjusted for 15 covariates: antidepressant type, age, sex, year of cohort entry, modified Charlson score (a co-morbidity index), and concurrent medication use (anticonvulsants, gabapentin, antipsychotics, barbiturates, benzodiazepines, histamine2-receptor antagonists, dopamine agonists, muscle relaxants, opioids and overactive bladder medications). Abbreviations: CI, confidence interval; CT, computed tomography.

Back to article page